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Abstract
Human herpesvirus 6 (HHV- 6A and HHV- 6B) can cause primary infection or reacti-
vate from latency in liver transplant recipients, which can result in a variety of clinical 
syndromes, including fever, hepatitis, encephalitis and higher rates of graft dysfunc-
tion as well as indirect effects including increased risks of mortality, CMV disease, 
hepatitis C progression and greater fibrosis scores. Although HHV- 6 infection is cur-
rently diagnosed by quantifying viral DNA in plasma or blood, biopsy to demonstrate 
histopathological effects of HHV- 6 remains the gold standard for diagnosis of end- 
organ disease. HHV- 6 reactivation may be restricted to the infected organ with no evi-
dence of active infection in the blood. HHV- 6 infections in liver transplant patients are 
mostly asymptomatic, but clinically significant tissue- invasive infections have been 
treated successfully with ganciclovir, foscarnet or cidofovir. Inherited chromosomally 
integrated HHV- 6 (ciHHV- 6), in either the recipient or the donor organ, may create 
confusion about systemic HHV- 6 infection. Recipients with inherited ciHHV- 6 may 
have an increased risk of opportunistic infection and graft rejection. This article re-
views the current scientific data on the clinical effects, risk factors, pathogenesis, diag-
nosis and treatment of HHV- 6 infections in liver transplant recipients.
K E Y W O R D S
chromosomally integrated HHV-6 (CIHHV-6), human herpesvirus 6 (HHV-6), liver 
transplantation
1  | INTRODUCTION
Human herpesvirus 6 (HHV- 6) is the common collective name for the 
two distinct viruses known as human herpesvirus 6A (HHV- 6A) and 
human herpesvirus 6B (HHV- 6B).1 HHV- 6A, HHV- 6B and HHV- 7 
make up the Roseolovirus genus, aetiological agents of roseola, a com-
mon disease in infants. Like other herpesviruses, HHV- 6 establishes 
life- long latency in human hosts and may reactivate under certain situ-
ations later in life. HHV- 6 is a ubiquitous virus that typically causes pri-
mary infection in children, most commonly before the age of 2 years.2 
Since over 95% of humans are infected, the vast majority of active 
HHV- 6 infections detected in adults are thought to be because of the 
reactivation of endogenous latent HHV- 6. However, primary HHV- 6 
infection can still occur in seronegative adults.3 Primary HHV- 6 in-
fection in children may manifest as non- specific fever, diarrhoea and 
rash (known as exanthema subitum or roseola infantum).4 HHV- 6 is 
the most common cause of hospital visits in infants with fever, ac-
counting for 20% of all cases of acute fever in children between 6 and 
12 months old.2,5 The absence of HHV- 6- specific antibodies during 
active viraemia is indicative of primary infection.
HHV- 6 reactivation is often diagnosed by testing for the presence 
of viral DNA in plasma, whole blood or peripheral blood mononuclear 
cells (PBMCs). HHV- 6 reactivation can also be identified by HHV- 6 an-
tigenaemia, demonstration of virus- specific proteins from tissue biop-
sies, or the detection of HHV- 6 messenger RNA. Since latent HHV- 6 
DNA is ubiquitous and clinically insignificant viral reactivation occurs 
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commonly in immunosuppressed patients, the interpretation of HHV- 6 
DNA in blood and/or liver tissue after liver transplantation is challenging. 
HHV- 6 infections are mostly asymptomatic, although clinically signifi-
cant HHV- 6 infections in liver transplant patients may be understated 
since an infection may be active in the liver without remarkable DNA 
levels in the PBMCs or plasma. HHV- 6A&B can infect hepatocytes and 
establish latency, where they can induce the release of cytokines that 
may cause hepatic cell injury.6–8 HHV- 6 infection can be treated with 
ganciclovir, foscarnet or cidofovir. We conducted a literature review to 
provide a state of the art evaluation of HHV- 6 in liver transplantation, 
including its epidemiology, clinical effects, diagnosis and treatment.
2  | HHV- 6 TRANSPLANT EPIDEMIOLOGY
HHV- 6 is often reactivated from latency during periods of intense im-
munosuppression, although sporadic cases of HHV- 6 reactivation have 
been reported even in the immunocompetent.9–12 HHV- 6A & B are 
increasingly recognized as pathogens that can cause primary infection 
or reactivate from latency in liver transplant recipients, resulting in a 
variety of adverse clinical syndromes including fever, hepatitis and en-
cephalitis, as well as higher rates of HCV progression and CMV reacti-
vation, graft failure and mortality. The virus found in liver transplants is 
almost always HHV- 6B.13–17 The frequency of HHV- 6 reactivation after 
liver transplantation is approximately the same in plasma (33%) and 
PBMCs (34%) (Table 2). Reported reactivation rates vary and depend on 
whether or not patients were administered CMV prophylaxis that effec-
tively covers HHV- 6. In the studies summarized in Table 3, 50 (11%) of 
the 455 patients receiving CMV prophylaxis reactivated HHV- 6 vs 167 
(39%) of the 433 patients receiving acyclovir or no prophylaxis.
Unique to HHV- 6 is the ability to integrate their viral genome into 
the human host chromosome. Known as inherited chromosomally inte-
grated HHV- 6 (ciHHV- 6), it is naturally passed through the germ line in 
a Mendelian fashion.18 The clinical consequences of ciHHV- 6 in the im-
munocompromised host are actively debated.19 Among liver transplant 
patients with ciHHV- 6, 2% are reported to present with extremely high 
viral loads in whole blood (>5.5 log10 copies/mL), compared to 0.85% in 
control patients20 indicating that almost 3% of liver transplants could be 
affected by ciHHV6 in either the donor or recipient. The ciHHV- 6 preva-
lence in the Mayo Clinic liver study21 was stated to be (1.3%) based on an 
arbitrary threshold of 1 million copies/mL. However, this threshold ex-
cluded a patient with over 5.5 log10 copies/mL who was likely ciHHV- 6+, 
suggesting that the true prevalence was probably 1.6% or twice the rate 
found in healthy controls. It is now known that the integrated virus can 
activate19 and may be stimulated by HDAC inhibitors and steroids.22
3  | CONDITIONS ASSOCIATED WITH HHV- 6 
IN LIVER TRANSPLANT PATIENTS
3.1 | Asymptomatic Infection
Many immunosuppressed transplant patients develop transient 
and asymptomatic HHV- 6 infections demonstrated by low- level 
quantitative PCR DNA levels.8,23 These transient reactivations do not 
require treatment.
3.2 | Fever
Patients with clinically significant HHV- 6 infection after liver trans-
plantation commonly present with unexplained fever.8,24,25 Among 
adult transplant patients with HHV- 6 plasma viraemia, five (29.4%) 
of 17 presented with unexplained fever at the time of reactivation.8 
Fever may be associated with skin rash,25,26 myelosuppression27 or 
elevated transaminases.28–30
3.3 | Hepatitis
HHV- 6 has been implicated as cause of hepatitis in solid organ 
transplant (SOT) patients.30,31 In liver transplant patients, HHV- 6 
reactivation is associated with elevated transaminases,11,28–30 portal 
lymphocytic infiltration on liver biopsy28,32 and acute rejection.15 One 
case report described an HHV- 6B infected liver transplant patient 
who developed donor- transmitted HHV- 6A superinfection that mani-
fested as syncytial giant cell hepatitis.30
A recent study found that HHV- 6 DNA was detectable in 10 of 
26 (38.5%) liver biopsy specimens diagnosed with graft acute hepati-
tis of undetermined origin.31 In 4 (40%) of the 10 patients, confluent 
periportal necrosis was associated with high tissue HHV- 6 viral load 
on liver biopsy. In contrast, periportal necrosis was absent in graft 
hepatitis not documented to be associated with HHV- 6. Hence, the 
presence of confluent periportal necrosis with high intragraft viral 
load may indicate HHV- 6- induced hepatitis. Notably, only 28.6% of 
patients with HHV- 6- positive graft hepatitis had elevated levels of 
HHV- 6 in the PBMCs associated with active infection. The authors 
concluded that in over two- thirds of cases, the reactivation of HHV- 6 
would have been missed if the testing had been performed only on 
the peripheral blood. The median viral load was 3.84 log 10 cop-
ies/106 cells.
Key points
• HHV-6 reactivation after liver transplantation is mostly 
asymptomatic but can be associated with fever, hepatitis 
and encephalitis.
• Tissue-invasive HHV-6 disease cannot be completely 
ruled out without a biopsy since infections can be local-
ized in the tissue without remarkable DNA levels in blood. 
Quantitative assays are essential to distinguish active 
from latent HHV-6 DNA.
• When testing for the presence of HHV-6, ciHHV-6 in 
 either donor or recipient must be considered.
• Symptomatic and tissue-invasive HHV-6 infections in 
liver transplant recipients can be successfully treated 
using ganciclovir, foscarnet or cidofovir.
212  |     PHAN et Al.
In a retrospective study of 121 liver transplant patients, HHV- 6 
infection was considered the cause of hepatitis after liver transplan-
tation in 8 (6.7%) patients, demonstrated by serology and immunos-
taining of HHV- 6 antigens in liver biopsy specimens.32 Two patients 
presented with a pure HHV- 6 infection (without concomitant CMV 
infection or rejection), both of whom had significant graft dysfunction. 
Of the eight patients, five demonstrated acute rejection and lympho-
cytic infiltration was observed in three patients.
3.4 | Encephalitis
HHV- 6 encephalitis is most often seen in cord blood (8%- 10%) and 
stem cell transplant patients (1%- 3%),33–35 but it has also been re-
ported in several liver transplant recipients. A retrospective review 
of medical and laboratory records reported a correlation between 
HHV- 6 infection and symptoms of encephalitis in seven (35%) of 20 
liver transplant patients.36 A case was reported in which a patient, 
transplanted for liver failure because of HCV, presented with fever, an 
erythematous macular rash on his trunk and back, mental confusion, 
agitation and visual hallucinations.37 Using nucleic acid testing, HHV- 6 
was detected in his plasma and cerebrospinal fluid (CSF). Testing was 
negative for CMV and EBV. Brain MRI demonstrated symmetric high 
signal intensity in the medial temporal lobes involving the bilateral 
amygdala and hippocampi, indicative of HHV- 6 encephalitis. The pa-
tient was successfully treated with foscarnet and a reduction in immu-
nosuppression. He had no significant neurological sequelae at 1- year 
follow- up. Two other case reports documented encephalitis after liver 
transplantation.38,39 Both patients were diagnosed with encephalitis 
after their CSF tested positive for HHV- 6 by PCR and other pathogens 
were ruled out and both were successfully treated with intravenous 
ganciclovir.
In 2011, a case of ganciclovir- resistant HHV- 6 encephalitis in a 
liver transplant patient was reported.40 This patient was on IV ganci-
clovir because of primary CMV disease until re- admission 2 months 
post- transplant when he presented with tonic- clonic seizures, altered 
mental status, agitation and neutropenia. CSF and plasma were posi-
tive for HHV- 6 by PCR and brain MRI revealed prominent multifocal 
T2 hyperintensities in the left mesial temporal lobe, pons and cere-
bellum, as well as bilateral parietal occipital hyperintensities. Since he 
acquired the infection while on IV ganciclovir, the patient was treated 
with foscarnet, with clinical improvement.
3.5 | Gastrointestinal Disease
HHV- 6 infection in liver transplant patients can present as colitis.41 In 
a retrospective study of 1345 patients who underwent HHV- 6 PCR 
testing at a French hospital between May 2003 and December 2004, 
43 samples from 25 patients (3%) were positive for HHV- 6.41 Nine of 
the 25 (36%) patients experienced gastrointestinal symptoms, includ-
ing 6 (67%) who presented with colitis, three of whom underwent liver 
transplantation. Another study analysed the gastroduodenal mucosa 
of biopsy samples obtained from 90 liver transplant recipients for 
HHV- 6 antigens.42 The researchers detected HHV- 6 antigens in 21 
patients, of whom 15 displayed simultaneous HHV- 6 antigenaemia. 
Histopathological findings in the HHV- 6- positive mucosa were non- 
specific and included very mild inflammation.
3.6 | Myelosuppression and Pneumonia
Myelosuppression has been attributed to HHV- 6 reactivation.43–45 In a 
report of four liver transplant recipients, HHV- 6 reactivation  occurred 
a median of 50 days post- transplant. Severe cytopenia was observed 
in all patients and leucopenia was the most commonly  effected bone 
marrow lineage.27 HHV- 6- associated interstitial pneumonitis  occurred 
in one of the four patients.27 HHV- 6 was documented by immunohis-
tochemical staining of lung tissue. No other pathogens were detected 
in the lungs, blood or bone marrow of these four patients.
3.7 | CMV co- infection and disease
Several studies have observed an association between HHV- 6 infec-
tion and CMV disease (Table 1). HHV- 6 antigenaemia regularly pre-
cedes CMV antigenaemia and has been implicated as the probable 
cause of graft dysfunction.46 A 2012 study of 45 liver transplant re-
cipients reported CMV infection in 23 (51.1%) and HHV- 6 infection 
in 12 (26.7%) patients.47 Of the six patients who displayed an acute 
cellular rejection episode, four had concomitant bacterial infections 
and three experienced graft rejection episodes.47 Those who reacti-
vated HHV- 6 were 3.5 times (P=.02) more likely to suffer from severe 
CMV- associated disease.48 In a prospective study of 33 consecutive 
liver transplants, HHV- 6 was detected in PBMCs by qualitative PCR 
in 11 (33%) patients.49 As is common with ubiquitous viruses, the as-
sociation between CMV and HHV- 6 was stronger when quantitative 
viral load, rather than qualitative DNA detection, was utilized. While 
high HHV- 6 viral loads were detected in 3 (27%) of 11 CMV donor+/
recipient- patients, high HHV- 6 levels were not detected in either 
15 CMV donor+/recipient+ or 7 CMV donor- /recipient- patients 
(P=.037).49 Of the 10 patients who had symptomatic CMV disease, 
four had high HHV- 6 levels (P=.02), and eight had either high HHV- 6 
or HHV- 7 levels (P<.0001).49 The results from these studies strongly 
suggest an interaction between β- herpesviruses, particularly HHV- 6 
and CMV. Symptoms primarily attributed to CMV may be the result 
of a co- infection and not just the effects of a CMV infection per se.
3.8 | Hepatitis C disease progression
One study observed that patients who underwent liver transplanta-
tion for cirrhosis caused by HBV or HCV were more likely to have 
an HHV- 6 infection (P=.025).8 However, the relationship between 
HHV- 6 and HCV is still not clearly defined and some studies50,51 
have observed no association between HCV recurrence and HHV- 6 
viral load. A study detected HHV- 6 DNA in 9/12 (75%) patients who 
suffered HCV recurrence (P=.049).52 HHV- 6 is also associated with 
higher fibrosis scores (Table 1). Patients undergoing liver transplanta-
tion for cirrhosis caused by HBV or HCV are more likely to have post- 
transplant HHV- 6 reactivation detected in the blood.8
     |  213PHAN et Al.
TABLE  1  Indirect Effects of HHV- 6 Infection
Condition Pts P- Value (<.05)
Univariate or 
multivariate Notes Refs.
Graft dysfunction 
& graft survival
170 .014 
.003
Univariate High liver biopsy HHV- 6 DNA levels (>75th percentile, 11.27 
copies/1000 cells) and detection of HHV- 6 in the peripheral 
blood were significantly associated with decreased graft 
survival after diagnosis of graft hepatitis (P=.014 and P=.003, 
respectively, median follow- up was 23.8 months).
[59]
41 .004 Univariate HHV- 6 was associated with rejection in 41 patients with 
rejection after 30 days. (P=.004). HHV- 6 was not associated 
with overall rejection (mean 13.5 days) since HHV- 6 mean 
reactivation occurred later (27 days).
[26]
CMV disease 200 .003 Univariate CMV viral load was significantly higher in patients with HHV- 6 
infection versus those without (P=.003).
[26]
88 .013 
.001
Univariate 
Univariate
Symptomatic CMV disease was more common in patients with 
HHV- 6 infection than it was in those without infection (P=.013). 
CMV viral load was higher in those with HHV- 6 infection 
(P=.001)
[96]
88 .013 Multivariate HHV- 6 infection remained an independent risk factor for CMV 
disease.
33 .022 Univariate This association with high levels (>5000 copies/PCR input) of 
HHV- 6 and HHV- 7 but not with qualitative detection.
[49]
41 .0128 Univariate There was a statistically significant difference in the presence of 
HHV- 6 DNA in pre- transplant graft biopsies between recipients 
who showed and did not show CMV disease after liver 
transplant (P<.0128).
[52]
139 .01 Univariate HHV- 6 reactivation was associated with CMV disease (P=.01) 
and severe CMV- associated disease (P=.01).
[48]
139 .02 Multivariate HHV- 6 reactivation remained significant in multivariate analysis 
(RR, 3.5; 95% CI, 1.2–10.2; P=.02)
HCV higher 
fibrosis score, 
recurrence
51 .01 Univariate Patients with HHV- 6 viraemia had a significantly higher fibrosis 
score upon HCV recurrence (mean 1.5 vs 0.3, P=.01).
[97]
66 .01 Univariate HHV- 6 infection was associated with the development of more 
severe recurrence (hepatitis and/or fibrosis score>2) (P=.01).
[98]
66 .031 Univariate Fibrosis scores at last follow- up were higher in patients with 
CMV disease and in patients with HHV- 6 infection (P=.031).
170 .031 Univariate Fibrosis scores at follow- up were higher in patients with HHV- 6 
infection (1.18 vs 0.55; P=.031).
[59]
Opportunistic 
infection
200 .001 
.001
Univariate 
Multivariate
Risk of opportunistic infection increased by 1.47 per log10 
increase in HHV- 6 viral load (P=.001). In a multivariate analysis 
designed to control for the level of immunosuppression, the risk 
of opportunistic infection increased by 3.68- fold in patients 
with HHV- 6 infection (P=.001)
[28]
80 .03 Univariate HHV- 6 infection was an independent predictor of invasive fungal 
infections (odds ratio 8.3, P=.03)
[55]
Mortality 170 .003 Univariate Detection of HHV- 6 DNA in blood samples was associated with 
a shorter survival in Kaplan Meier analysis (P=.003 log rank).
[59]
67 .0118 Univariate 11/26 (42.3%) of HHV- 6 reactivated recipients died compared to 
only 6/41 (14.6%) without reactivation
[8]
67 .0114 Multivariate HHV- 6 reactivation was an independent risk factor for increasing 
the mortality (P=.014)
80 .04 
.008
Univariate 
Univariate
Mortality rate at 3 months in patients with HHV- 6 infection was 
significantly higher than those without HHV- 6 infection (P=.04). 
This association was even more significant at last follow- up 
(29% mortality in HHV- 6+ patients vs 6% mortality in 
HHV- 6- patients) (P=.008)
[55]
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3.9 | Immunosuppression resulting in fungal and 
opportunistic infections
HHV- 6 can counter the human immune system’s ability to eradicate 
the virus in many ways45,53 and is thought to impact the occurrence of 
opportunistic infections in patients after liver transplantation.44 Liver 
transplantation has been shown to suppress HHV- 6- specific memory 
response and in one study, only one (7%) of 15 liver transplant patients 
exhibited an effective proliferative response at 2 weeks compared to 
64% matched healthy subjects. This deficit persisted at 2- 3 months and 
at 1- year post- transplant, with only 25% of patients exhibiting an HHV- 
6- specific memory response, whereas the recovery of the memory re-
sponse to CMV was much more robust. The lack of T- helper cell response 
to HHV- 6 was not because of overall reduced responsiveness where the 
patients lacked the ability to respond to any or all stimuli.54 HHV- 6s im-
munosuppressive effect has been confirmed in recent studies.45
A study of 200 liver transplant recipients demonstrated HHV- 6 infec-
tion was associated with opportunistic infections, including CMV, EBV- 
related post- transplant lymphoproliferative disease, VZV, invasive fungal 
infections and mycobacterial disease.28 Multivariate analysis showed 
that the risk of opportunistic infection increased by 1.47 per log10 in-
crease in HHV- 6 viral load (P=.001). HHV- 6 was the only predictive 
factor of opportunistic infections excluding CMV (odds ratio 3.33; 95% 
CI 1.55- 7.14; P=.002).28 Another prospective study found that HHV- 6 
infection was an independent predictor of invasive fungal infection in 
a cohort of 80 consecutive liver transplants (odds ratio 8.3, 95% CI 1.2- 
58.0, P=.03).55 Furthermore, a prospective study of 548 liver transplant 
recipients detected ciHHV- 6 in seven patients, low- level DNAemia in 35 
patients and no HHV- 6 DNAemia in 506 patients prior to transplant.21 
Bacterial infection was significantly more common in the ciHHV- 6 group 
compared to the group without HHV- 6 (71.4% vs 31.4%, P=.04).
3.10 | Allograft rejection and survival
HHV- 6 infection in the liver allograft increases expression of adhesion 
molecules56,57 on vascular endothelial cells and infiltrating leucocytes, 
which could lead to local inflammation and graft damage and result in 
graft dysfunction or rejection.58 A study of 170 adult liver transplant 
recipients with graft hepatitis demonstrated that high intrahepatic 
HHV- 6 DNA levels (P=.014) and HHV- 6 DNAemia (P=.003) were sig-
nificantly associated with decreased graft survival.59 The probability 
of graft survival was less than 60% at 500 days in those with high 
HHV- 6 levels in the liver graft (>75th percentile: 11.27 copies/103 
cells) and was only 40% at 500 days in those with HHV- 6 found in 
the peripheral blood (compared to over 80% in controls). A study of 
200 patients using qualitative PCR found that HHV- 6 in the plasma 
was not associated with graft rejection when early rejections (mean 
13.5 days) before HHV- 6 reactivation (mean 27 days) were included. 
However, when 41 cases of rejection post day 30 were analysed, 
HHV- 6 viral load was an independent predictor of rejection (odds 
ratio 2.27, 95% CI 1.09- 4.77; P=.029).28 A study of 59 liver transplant 
patients found that HLA- DR15 was associated with HHV- 6 positiv-
ity in donor biopsies and that patients with HLA- DR15 in liver donor 
biopsies developed more rejection after liver transplantation.60 In a 
study of 33 paediatric liver transplant recipients, HHV- 6 was detected 
in 3 (9.1%) patients and HHV- 6 infection was associated with concur-
rent episodes of moderate to severe acute graft rejection in two of 
the three children.15 Finally, a prospective study of 548 liver trans-
plant recipients reported a higher rate of allograft rejection in patients 
with ciHHV- 6 (71.4%) compared to patients with low level HHV- 6 
DNAemia (37.1%) and patients with no HHV- 6 DNAemia (42.9%).21
3.11 | Mortality
All- cause mortality is higher in patients after liver transplantation with 
HHV- 6 reactivation or infection (Table 1).8,55,59 A Japanese study8 of 
67 liver transplant recipients found that mortality was significantly 
higher at the last follow- up among patients with HHV- 6 reactivation 
(P=.0118) and that HHV- 6 reactivation was an independent risk factor 
for increasing mortality (P=.014). Another study reported that mortal-
ity rate at 3 months in patients with HHV- 6 infection was significantly 
higher than that of patients without HHV- 6 infection (P=.04). This as-
sociation was even more significant at last follow- up (29% mortality 
in HHV- 6+ patients vs 6% mortality in HHV- 6- patients; P=.008).55
4  | RISK FACTORS ASSOCIATED WITH 
ACTIVE HHV- 6 INFECTION IN LIVER 
TRANSPLANTATION
4.1 | HHV- 6 seronegativity
The frequency of HHV- 6 seronegativity in adult solid organ trans-
plants is very low (3.6%) and the risk of HHV6 disease is low.61 In 
contrast, HHV- 6 seronegativity is higher in paediatric liver transplant 
patients and an important factor for primary HHV- 6 infection. One 
study found that five out of six (83%) seronegative paediatric living- 
related liver transplant recipients developed primary HHV- 6 infection 
after transplantation.24 A study conducted in a large paediatric trans-
plant centre found that 27 of 66 (40.9%) paediatric liver transplant 
recipients were seronegative for HHV- 6 pretransplant.62 Of 18 seron-
egative patients tested after transplant, nine (50%) developed HHV- 6 
primary infection, whereas of 24 seropositive patients tested, only five 
(17.2%) developed HHV- 6 reactivation.62 This study determined that 
HHV- 6 seronegative liver transplant patients presented HHV- 6 infec-
tion earlier (median: 2 weeks, range: 2 weeks- 2 months) than HHV- 6 
seropositive patients (median: 2.5 months, range: 3 weeks- 9 months) 
and that HHV- 6 seronegative patients had more severe symptoms.
In general, the frequency of HHV- 6 plasma viraemia is lower in 
adult liver transplant recipients than in paediatric liver transplant re-
cipients.8 One key study directly compared a group of 17 paediatric 
liver transplant recipients to 17 adult liver transplant recipients and 
found that only 11.8% of adults presented with HHV- 6 viraemia com-
pared to 29.4% of children.63 One study reported that 49% of paedi-
atric liver transplant recipients experienced HHV- 6 plasma viraemia 
(reactivation) even though 85% of them were seropositive for HHV- 6 
at the time of transplantation (Tables 2 and 3).24
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4.2 | Immunosuppressive Agents
A study of 92 HCV- infected liver transplant recipients reported that 
patients with HHV- 6 reactivation received higher doses of steroids 
(P=.032).50 Hydrocortisone activates HHV- 6 in vitro64 and studies of 
cases of severe drug hypersensitivity have shown that patients re-
ceiving systemic corticosteroids disproportionately reactivate HHV- 6 
compared to EBV and CMV.65
T- cell defects are associated with HHV- 6 reactivation. For example 
Muromonab- CD3 (OKT3) is an immunosuppressant drug previously 
used to reduce acute rejection in liver transplant patients. A retrospec-
tive analysis of serial serum samples drawn from 139 liver transplant 
recipients involved in a prospective trial on CMV reported that the 
use of OKT3 for rejection treatment was significantly associated with 
HHV- 6 reactivation, defined as a four- fold increase in HHV- 6 IgG and/
or the presence of HHV- 6 IgM.48 Thirty- six (41.4%) of 87 patients with 
HHV- 6 reactivation received OKT3 versus 11 (21.2%) of 52 without 
HHV- 6 reactivation (P=.02).
4.3 | Pre- transplant HHV- 6 reactivation
Pretransplant hepatic HHV- 6 infection in patients with acute liver fail-
ure (ALF) may be a risk factor for HHV- 6 infection of the liver graft 
post- transplant. Several studies have identified HHV- 6 reactivation in 
patients with ALF of unknown cause, but not in patients with liver 
failure with known aetiology. In a study of 32 liver explants for ALF 
patients, HHV- 6 antigens were detected, using immunoperoxidase 
staining, in both hepatocytes and infiltrating lymphocytes in the portal 
area of 12 (80%) of 15 patients who underwent liver transplantation 
owing to ALF of unknown cause. HHV- 6 antigens were observed in 
only four (23.5%) of 17 control patients with a known cause of ALF.66 
The predominant histological finding of HHV- 6 infection was moder-
ate to severe portal lymphocytic infiltration although some hepato-
cytes were also antigen- positive. Notably, 80% of patients with 
HHV- 6 positive explants also showed evidence of HHV- 6 reactivation 
in testing prior to the transplant.66 In a follow- up study,67 researchers 
found HHV- 6 in nine (50%) of the 18 post- transplant biopsies. No 
post- transplant HHV- 6 infections were observed in patients without 
evidence of HHV- 6 in their pretransplant biopsies.
4.4 | Inherited chromosomally integrated HHV- 6 
(ciHHV- 6)- positive donor organs & recipients
Although further study is required, it is possible that active HHV- 6 in-
fection could be transmitted horizontally by donated ciHHV- 6- positive 
organs. Two such cases were reported at the 9th International HHV- 6 
Conference in 2015.68 Sequencing of the DNA confirmed that in both 
cases, the virus of the donor liver could be found in several compartments 
of the recipient. In the first patient, a 5- year- old receiving a ciHHV- 6B+ 
liver, the persistent HHV- 6B plasma viraemia (1.8 × 103 − 3.6 × 103 cop-
ies/mL) that developed 18 months post- transplant was suspected to cor-
respond to incidental ciHHV- 6B hepatocyte lysis rather than production 
of infectious particles by infected cells. The second patient, a 53- year- old 
with cirrhosis who acquired HHV- 6A from the transplant, had very high 
viral loads of HHV- 6A in CSF and gastrointestinal tract, suggesting a 
massive reactivation associated with delirium and profuse diarrhoea.
References Prophylaxis
Total liver 
transplant patients HHV- 6 Reactivated % Reactivated
[96] GCV/VGV 23 1 4.3%
[15] GCV 33 3 9.1%
[50]c,g GCV 14 3 21.4%
[28]h GCV 31 4 12.9%
[29] GCV 154 25 16.2%
[51]f GCV/VGV 177 13 7.3%
[14] GCV/VGV 23 1 4.3%
Totals for CMV prophylaxis 455 50 11%
[28]h None 169 52 30.8%
[50]c,g ACV 76 33 43.4%
[24] ACV 47 23 48.9%
[8] ACV 67 26 38.8%
[49]c ACV 33 11 33.3%
[14] None 41 22 53.7%
Totals for no CMV 
prophylaxis
433 167 39%
Reference [31] was omitted from this table due to insufficient data regarding prophylaxis administered 
to the two patients who had HHV- 6 detected in PBMCs. Reference [22] was omitted from this table 
due to insufficient data regarding which patients received ACV/GCV vs ACV only. Reference [93] was 
omitted from this table because it is a study of a subset of the population in reference 27, which has 
been included in this table.
TABLE  3 Frequency of HHV- 6 
Viraemia in liver transplant patients 
(separated by CMV Prophylaxis [GCV/
VGV])
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5  | DIAGNOSIS
5.1 | Polymerase chain reaction (PCR)
Laboratories in North America and Japan typically use real- time quan-
titative PCR on plasma whereas in Europe whole blood testing is more 
common. PCR can be performed on whole blood, plasma, PBMCs 
and biopsy tissue samples. Most centres view any HHV- 6- positive 
result in plasma or CSF as a sign of clinically significant active infec-
tion, whereas whole blood assays require a threshold to determine a 
meaningful clinical reactivation.69 Using PCR, the frequency of HHV- 6 
detection in plasma (33%) vs PBMCs (34%) from liver transplant pa-
tients is essentially the same (Table 2), whereas the rate for whole 
blood (19%) is lower. HHV- 6 viral loads in liver transplant patients 
vary (Table 2) and CMV prophylaxis greatly affects the frequency of 
HHV- 6 reactivation (Table 3). HHV- 6 is highly cell- associated and 
HHV- 6 DNA may not be detectable or elevated in plasma or PBMC 
testing, in spite of a persistent infection.31 In persistent HHV- 6 in-
fections, only biopsy analysis can rule out an HHV- 6 infection. Buyse 
et al. found two distinct patterns in liver biopsies of patients positive 
for HHV- 6: (i) those with a high viral load (4 log10 copies/10
6 cells) had 
severe periportal activity; (ii) those with a lower viral load had lobular 
activity with mild to moderate portal inflammatory infiltrates.31
Patients with persistently high levels of plasma DNA should be 
tested for ciHHV- 6 using whole blood or PBMCs. Whole blood HHV- 6 
DNA levels above log 5.5 copies/ml should be assumed to be ciHHV6. 
Any level of HHV- 6 DNA in CSF could be assumed to be from an ac-
tive infection and treatment should be considered if symptoms are 
suggestive of HHV- 6 encephalitis. Patients positive for ciHHV- 6 may 
have a low level of HHV- 6 DNA in CSF owing to normal cell lysis. If 
there are a large number of cells as a result of blood in the CSF sample, 
the viral load can be significant.
Although PCR assays are commercially available, they are still out-
numbered by in- house developed assays,70 resulting in inconsistent di-
agnostic testing. An international study comparing HHV- 6 PCR assays 
from 51 different laboratories revealed extensive interlaboratory vari-
ation in quantitative PCR results, with the standard deviation ranging 
from 0.5 log10 copies/mL to 0.7 log10 copies/mL. All the commercial 
assays reported correct results, compared to 96.1% of the in- house 
real- time assays and conventional in- house assays, suggesting that 
commercial assays may have a higher sensitivity.71 In addition, HHV- 6 
PCR results are variably reported as copies/mL plasma or per one mil-
lion peripheral blood lymphocytes.72 Clinically significant HHV- 6 DNA 
levels remain to be determined in liver transplant recipients.26,59,63 
Pischke et al. suggested that high intrahepatic viral loads (>11.27 cop-
ies/1000 cells was an independent factor associated with decreased 
graft survival.59 International laboratory standards do not exist but are 
currently in development.70
5.2 | Liver biopsy tissue testing
Detection of HHV- 6 DNA in the patient’s plasma or CSF indicates 
an active infection. However, HHV- 6- associated liver disease T
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TABLE  5 Antiviral therapy in liver transplant recipients
Antiviral treatment Age/sex Indication for treatment/key findings Imp.d? Refs.
Valganciclovir 16 years/M 14 611 copies HHV- 6 DNA/106 cells in liver biopsy. Fever, abnormal liver 
tests, hepatitis/severe portal inflammation, severe periportal necrosis, 
moderate lobular necrosis, <5% confluent necrosis.
Yes [31]
60 years/M Positive HHV- 6 viraemia. Elevated liver enzymes, fatigue, malaise, dizziness, 
abdominal bloating.
Yes [100]
Intravenous 
ganciclovir
10 months/M HHV- 6 load in liver biopsy: 8125 copies/106 cells, HHV- 6 Load in PBMCs: 
negative. Fever + macular rash (15 days), elevated liver enzymes, abnormal 
bilirubin.
Yes [26]
8 months/M HHV- 6 load in liver biopsy: 1371 copies/106 cells, HHV- 6 Load in PBMCs: 
6643 copies/106 cells. Fever (4 days), elevated liver enzymes, abnormal 
bilirubin.
No
7 months/M HHV- 6 load in Liver biopsy: 13 768 copies/106 cells, HHV- 6 Load in PBMCs: 
10 000 copies/106 cells. Fever (3 days), elevated liver enzymes, abnormal 
bilirubin.
No
43 years/M 44 000 gEq HHV- 6A/μg of DNA in paraffin embedded liver biopsy sample. 
Fever, mild neutrophil leucocytosis, elevated liver enzymes, syncytial 
giant- cell hepatitis.
Yes [30]
44 years/F 12 434 copies HHV- 6 DNA/106 cells. Hepatitis, fever, elevated liver enzymes/
moderate portal inflammation, severe periportal necrosis, 10% confluent 
necrosis, moderate lobular necrosis.
Yes [31]
61 years/M CSF was positive for HHV- 6. Confusion, diffuse erythematous cutaneous rash/
MRI brain showed bilateral and symmetrical increased T2 signal, with 
non- enhancing lesions in the temporal lobe and hippocampal gyrus of both 
hemispheres. Skin biopsy was compatible with GVHD.
Yes [38]
49 years/M CSF was positive for HHV- 6. Fever, confusion, occipital headaches, involun-
tary movements of the arms and legs.
Yes [39]
7 months/F HHV- 6 Antibody Titres (peak levels): IgG 32, IgM 8. HHV- 6 PCR was positive 
on day 14 via nested- PCR, fever (day 5- 12)
Yes [79]
8 months/F Peak HHV- 6 DNA in liver biopsy was >1000 copies/105 PBMCs; peak HHV- 6 
DNA in plasma was 10- 100 copies/105 PBMCs. Fever, petechiae, leucopenia, 
thrombocytopenia, elevated liver enzymes.
Yes [90]
Intravenous 
ganciclovir/
valganciclovir
58 years/F 15 096 copies HHV- 6 DNA/106 cells in liver biopsy. Elevated liver enzymes/
moderate portal inflammation, moderate periportal necrosis, mild lobular 
necrosis.
Yes [31]
38 years/F 7036 copies HHV- 6 DNA/106 cells in liver biopsy. Abnormal AST/severe 
portal inflammation, severe, periportal necrosis, moderate lobular necrosis.
Yes
Cidofovir/
valganciclovir
45 years/M 198 000 copies HHV- 6 DNA/106 cells in liver biopsy. Leucopenia, abnormal 
liver enzymes/Mild portal inflammation, moderate lobular necrosis.
Yes [31]
Cidofovir 2.3 years/Fa HHV- 6 DNA was detected in leucocytes, pleural effusions, BAL and liver 
biopsy. High fever, necrotic hepatitis, graft dysfunction, respiratory failure, 
pneumonitis, pleural effusion, highly inflammatory skin rash.
Yes [25]
Ganciclovir/
foscarnet
55 years/M 183 000 HHV- 6 DNA copies/mL in plasma, 7300 HHV- 6 DNA copies/mL in 
CSF. Fever, erythematous macular rash on trunk and back, confusion, 
agitation, visual hallucinations, leucopenia, mild thrombocytopenia/MRI brain 
showed symmetric high signal intensity in the medial temporal lobes involving 
the bilateral amygdala and hippocampi consistent with HHV- 6 encephalitis.
Yes [37]
71 years/Mb 1162 HHV- 6 DNA copies/mL CSF; 252 240 HHV- 6 DNA copies/mL plasma. 
Tonic- clonic seizures, altered mental status, agitation and inability to protect 
his airway, cough/abnormal EEG. MRI brain revealed multifocal T2 hyperin-
tensities most prominent in the left mesial temporal lobe, pons and cerebel-
lum, as well as bilateral parietal occipital hyperintensities.
Yes [40]
43 years/M Lumbar puncture in December 2000 revealed positivity for HHV- 6 at 7992 gc/
mL. Plasma HHV- 6 levels in July 2007 was 7364 gc/mL. Fever, diarrhoea, 
worsening HHV- 6 viraemia despite antiviral therapy. Quantification of 
HHV- 6 on hair resulted 11 159 420 gc/106 cells, consistent with ciHHV- 6.
No [82]
(Continues)
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cannot be ruled out in the absence of a biopsy even when there is 
no detectable viraemia.11,26,31 Within the same patient groups, the 
rates of detection have been approximately 56.8% in tissue biop-
sies (range 20% to 100%) vs only 17.6% in blood samples (range 
10% to 83.3%) (Table 4). If HHV- 6- induced liver dysfunction is sus-
pected, liver tissue will be more revealing than plasma or serum, 
although both should still be tested for HHV- 6. Taking up to three 
biopsy specimens can improve diagnostic yield.73 This is true with 
other organs as well, especially during persistent infections: HHV- 6 
DNA can be found in lung biopsies but not the plasma of patients 
with “idiopathic” pneumonia syndrome after lung transplantation74 
and high levels of DNA can be found in biopsy tissues of patients 
with persistent HHV- 6 myocarditis, in spite of little or no DNA in 
the plasma.9
Immunohistochemical (IHC) staining of biopsy specimens can de-
termine if the virus was active by staining for viral proteins.66 It is also 
possible to use virus- specific monoclonal antibodies to distinguish 
between HHV- 6A and HHV- 6B variants. Fluorescent in situ hybrid-
ization (FISH) can be used to isolate HHV- 6 positive cells.75 In FISH, 
fluorescent probes are hybridized to specific sequences of the HHV- 6 
genome in the tissue sample and fluorescence microscopy is then used 
to locate the where the probe is bound to the genome. Both IHC and 
FISH are useful for localizing the virus to specific cells and FISH can 
identify the cellular distribution of HHV- 6 DNA.
HHV- 6B has been detected in hepatocytes by in situ hybridization 
(ISH)13,76,77 and was found to be more prominent in hepatocytes than 
in intrahepatic mononuclear cells in two studies.13,76 In one patient, 
ISH localized DNA and RNA in the hepatocyte nuclei and envelope 
antigen was detected in the hepatocyte cytoplasm.
HHV- 6B has been found in sinusoidal mononuclear cells13,46 and 
in the nuclei of epithelial cells in the intrahepatic bile ducts.76,77 One 
study detected viral RNA in the nuclei of hepatocytes, but did not ob-
serve positive signals for DNA or RNA in infiltrating lymphocytes or 
other cell types in either biopsy specimens or in control patients.76
5.3 | Antigenaemia test
HHV- 6 antigens can be detected in both whole blood and tissue bi-
opsy specimens.16,66 The antigenaemia test is based on demonstration 
of HHV- 6 antigens in PBMCs using specific monoclonal antibodies 
and immunoperoxidase staining. The same method can be used for 
histochemical staining to detect HHV- 6 antigens in liver biopsies. 
Antigen testing can indicate active infection and distinguish HHV- 6A 
and HHV- 6B, although it is labour intensive, semi- quantitative and not 
commercially available.58,78
5.4 | Serology
Although serological assays for HHV- 6 are available for clinical use, 
they are not widely used in the liver transplant setting. Assays include 
immunofluorescence assays (IFA) and enzyme- linked immunosorbent 
assay (ELISA). Positive HHV- 6 IgM antibodies indicate active infec-
tion48; they appear transiently 2- 4 weeks after primary infection or 
acute reactivations,79 but do not persist in chronic infections. Thus, 
anti- HHV- 6 IgM is of limited value for diagnosing HHV- 6 reactiva-
tion in adult patients. In primary infection and acute reactivation IgG 
antibody titres typically increase four- fold within 4- 6 weeks.24,80 IgG 
serology cannot distinguish between HHV- 6A and B.
5.5 | Identifying inherited chromosomally integrated 
HHV- 6 (ciHHV- 6)
It is important to consider the possibility of inherited chromosomally 
integrated HHV- 6 in any patient with a persistently high HHV- 6 viral 
load. Determining ciHHV- 6 status will help the physician make a more 
informed decision on antiviral treatment, which is sometimes unnec-
essary or prolonged. Determining ciHHV- 6 status can alert the physi-
cian to cease further qPCR DNA testing as ciHHV- 6+ patients will 
consistently have high background levels of HHV- 6 DNA. Screening 
can be done with a quantitative whole blood PCR DNA test. HHV- 6 
levels in whole blood that exceed 5.5 log10
 copies/mL can be assumed 
to be ciHHV- 620 and organs will have ≥1 HHV- 6 genome/cell. Droplet 
digital PCR testing81 or a positive qualitative test of HHV- 6 in hair 
follicles or fingernails can confirm the diagnosis.20 Failure to recog-
nize ciHHV- 6 can result in patients being treated unnecessarily with 
toxic antivirals.82 HHV- 6 mRNA testing, can determine if HHV- 6 is 
actively replicating. Some experts have called for screening of all pa-
tients and donor organs or cells for ciHHV6.83,84 Although antiviral 
therapy has been associated with clinical improvement of ciHHV- 6+ 
patients,19,85–87 a report of 21 transplant recipients, including five liver 
and two combined liver- kidney, highlights the common misdiagnosis 
of ciHHV- 6 as active HHV- 6 infection.88
Antiviral treatment Age/sex Indication for treatment/key findings Imp.d? Refs.
Acyclovirc/
intravenous 
ganciclovir
32 years/F 171 959 HHV- 6 DNA copies/105 cells in liver biopsy, consistent negative 
HHV- 6 tests in PBLs. Influenza- like syndrome with fever, associated with a 
non- specific skin rash, jaundice, abnormal liver enzymes and bilirubin levels, 
hepatic encephalopathy.
Yes [11]
Totals 19 patients 16/19 (84%)
aPatient showed enhanced body weight normalized clearance of cidofovir and required a dosage increase from 5 mg/kg/week to 12 mg/kg/week.
bPatient acquired HHV- 6 infection while on ganciclovir for CMV infection and was subsequently treated with foscarnet.
cAcyclovir is not active against HHV- 6.
dImprovement is defined as the resolution of symptoms after antiviral therapy and no HHV- 6 disease- associated mortality.
TABLE  5  (Continued)
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6  | TREATMENT AND PREVENTION
Clinically significant HHV- 6 infections in liver transplant patients can 
be treated with antiviral drugs and a reduction in immunosuppres-
sive therapy. However, there are currently no FDA- approved antiviral 
drugs for the treatment of HHV- 6 infection. Ganciclovir, cidofovir and 
foscarnet have shown efficacy against HHV- 6 in vitro89 and are used 
to treat HHV- 6 in the clinical setting (Table 5). Of the 19 case reports 
included in Table 5, 16 (84%) improved after antiviral therapy.
6.1 | Ganciclovir (GCV) and valganciclovir (VCV)
Ganciclovir and valganciclovir are the most treatments for HHV- 6 in-
fection in liver transplant patients.30,38,90 HHV- 6 strains with muta-
tions in U38 DNA polymerase or in U69 phosphotransferase gene have 
demonstrated antiviral resistance to ganciclovir.58 Mutations in the 
U38 gene (P462S and A565V) confer resistance to ganciclovir only,91 
whereas an R798I amino acid change confers resistance to both ganci-
clovir and cidofovir.92 Treatment with ganciclovir has a relatively high 
success rate (Table 5) although cases of ganciclovir- resistant HHV- 6 
disease in liver transplant patients have been reported.40
6.2 | Cidofovir
Cidofovir has been successfully used to treat clinical HHV- 6 infec-
tions (Table 5). HHV- 6 strains with a mutation (R798I) in the U38 
DNA polymerase gene have demonstrated antiviral resistance to ci-
dofovir and ganciclovir.58,92 Thus, if cidofovir resistance is suspected, 
foscarnet should be the next line of therapy. Nephrotoxicity is the 
most common serious adverse effect of cidofovir,93 which should be 
used with caution when concomitantly administrated with potentially 
nephrotoxic agents (including but not limited to foscarnet, antibiotics 
and NSAIDs).
6.3 | Foscarnet (PFA or phosphonoformate)
Foscarnet is considered the most selective in vitro inhibitor of HHV- 6 
among the three drugs currently used to clinically treat active HHV- 6 
infections.94 Foscarnet selectively inhibits pyrophosphate binding on 
viral DNA polymerases. Mutations in U38 DNA polymerase (T435R, 
H507Y, C525S, located in the deltaC conserved domain and F292S) 
provides HHV- 6 antiviral resistance to foscarnet,95 which are distinct 
from the U38 mutations that confer resistance to cidofovir and ganci-
clovir.58,91,92 Foscarnet is the preferential treatment option for HHV- 6 
encephalitis in patients with anaemia, as administration of ganciclovir 
poses an additionally risk of dose- limiting haematological toxicity. Both 
drugs are able to penetrate the blood- brain barrier.84 Risks associated 
with foscarnet include complications from catheter- related deep vein 
thrombosis and infection.84 Nephrotoxicity is the most common se-
rious adverse effect of foscarnet, affecting 30% of patients, and is 
caused by deposition of foscarnet crystals in the glomerular capillary 
lumen.93 Foscarnet can also chelate bivalent metal ions and may lead 
to reductions in ionized calcium. Other electrolyte disturbances are 
hypokalaemia, hypomagnesaemia and hypophosphatasaemia, which 
can manifest as paresthesias, cardiac dysrhythmias and neurological 
symptoms, including seizures.93 Unlike cidofovir, foscarnet cannot be 
administered in a peripheral vein.94
6.4 | Prophylaxis
There are no standard guidelines that recommend prophylaxis against 
HHV- 6 in liver transplant patients since the prophylaxis for CMV also 
covers HHV- 6 (Table 3). Investigators who conducted a study of 34 
paediatric liver transplant patients using routine antiviral prophylaxis 
for CMV reported a low frequency of HHV- 6 DNA detection in whole 
blood (16%) post- transplant and an even lower frequency of plasma 
viraemia (2.6%), and hypothesized that these low rates may have been 
in part because of the ganciclovir treatment.29 A study of 129 adult 
liver transplant patients found that monitoring for HHV- 6 in liver 
transplant patients did not significantly alter the primary outcome. 
CMV prophylaxis (valganciclovir) was administered to 39% of the non- 
monitored group and 30% of the monitored group, and only one out 
of 23 episodes (4.3%) of HHV- 6 viraemia occurred in patients receiv-
ing prophylaxis (Table 3).14 Another study of 23 paediatric liver trans-
plant patients who received ganciclovir/valganciclovir prophylaxis, 
reported similar results, detecting HHV- 6 in just one patient (4.3%).96
6.5 | Viral monitoring and preemptive therapy
Monitoring for HHV- 6 viraemia is not routinely recommended. A 
Japanese study monitoring 34 liver transplant recipients (17 adult, 17 
paediatric) not given antiviral prophylaxis detected HHV- 6 in 20.6% of 
patients and viraemia occurred briefly without clinical symptoms.63 A 
recent study of 129 liver transplant recipients compared the outcomes 
of 64 patients monitored for HHV- 6 viraemia with the outcomes of 65 
patients not monitored for HHV- 6 viraemia.14 There were no differ-
ences in cumulative incidence of primary outcome between the moni-
tored and non- monitored groups at 1- year or 5- year post- transplant. 
However, a trend towards a lower incidence of graft rejection at year 
1 post- transplant (P=.091) and a significantly lower cumulative inci-
dence of biopsy proven acute graft rejection in the monitoring group 
(P=.026) were observed. This study reported only 1 of 23 episodes of 
HHV- 6 viraemia in patients on valganciclovir prophylaxis.14
7  | SUMMARY
Although acute clinical disease attributed to HHV- 6 after liver trans-
plantation is rare, HHV- 6 infections may impact the liver transplant 
patient. This review indicates that HHV- 6 reactivation in liver trans-
plant recipients is associated with significant increases in graft failure, 
mortality, hepatitis C progression and fibrosis and CMV disease.97–100 
Risk factors include steroid usage, HHV- 6 seronegativity, hepatitis B 
or C and immunosuppressive agents such alemtuzumab. HHV- 6 virae-
mia may occur more frequently in paediatric patients than in adults, 
owing to the occurrence of HHV- 6 primary infection in the paediatric 
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population. HHV- 6 may be an underappreciated cause of acute liver 
failure of unknown aetiology and pretransplant HHV- 6 infection in 
patients with ALF may be a risk factor for HHV- 6 infection of the liver 
graft post- transplant. Elevated HHV- 6 DNA load in biopsy samples is 
associated with decreased graft survival and mortality. Although acute 
systemic HHV- 6 infection is currently diagnosed by quantifying viral 
DNA in plasma or blood, HHV- 6 infection can persist in lung, liver, 
heart and brain tissues. In these cases, DNA is undetectable in the 
plasma so biopsy remains the gold standard for diagnosis of end- organ 
disease. HHV- 6 reactivation in the graft cannot be ruled out in the 
absence of a biopsy. HHV- 6 infections in liver transplant patients can 
be treated successfully with CMV antivirals ganciclovir, cidofovir or 
foscarnet. Ganciclovir prophylaxis appears to add protection against 
HHV- 6 as well as CMV.
Inherited chromosomally integrated HHV- 6 complicates interpre-
tation of HHV- 6 positive samples as the inherited virus can activate 
from its integrated state during immunosuppression.19 Further study 
is required to determine if ciHHV- 6+ organs should be monitored for 
reactivation or given antiviral prophylaxis.83,84
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